Efficacy of partially hydrolyzed guar gum (PHGG) supplemented modified oral rehydration solution in the treatment of severely malnourished children with watery diarrhoea: a randomised double-blind controlled trial

被引:16
|
作者
Alam, Nur Haque [1 ]
Ashraf, Hasan [1 ]
Kamruzzaman, Mohammad [1 ]
Ahmed, Tahmeed [1 ]
Islam, Sufia [2 ]
Olesen, Maryam Kadjar [3 ]
Gyr, Niklaus [4 ]
Meier, Remy [5 ]
机构
[1] Icddr B, Dhaka, Bangladesh
[2] East West Univ, Dept Pharm, Dhaka, Bangladesh
[3] Nestle Hlth Care Nutr, Gland, Switzerland
[4] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland
[5] Kantonsspital, Dept Gastroenterol Hepatol & Nutr, Liestal, Switzerland
关键词
Diarrhoea; Severe malnutrition; Children; Partially hydrolyzed guar gum (PHGG); CHAIN FATTY-ACIDS; AMYLASE-RESISTANT STARCH; PERSISTENT DIARRHEA; CHILDHOOD DIARRHEA; RURAL BANGLADESH; GREEN BANANA; MANAGEMENT; COLON; ABSORPTION; MALNUTRITION;
D O I
10.1186/s41043-015-0003-3
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Objectives: To examine whether PHGG added ORS reduce duration of diarrhoea, stool output and enhance weight gain. Methods: In a double-blind controlled clinical trial, 126 malnourished children (weight for length/weight for age < -3 Z-score with or without pedal edema), aged 6 - 36 months with acute diarrhoea < 7 days were studied in two treatment groups; 63 received modified WHO ORS (Na 75, K 40, Cl 87, citrate 7, glucose 90 mmol/L) with PHGG 15 g/L (study group); 63 received modified WHO ORS without PHGG (control). Other treatments were similar in both groups. The study protocol was approved by Ethics Committee of icddr,b; the study was carried out at the Dhaka Hospital. Results: The mean duration of diarrhoea (h) was significantly shorter in children of the study group (Study vs. control, mean +/- SD, 57 +/- 31 vs. 75 +/- 39, p = 0.01). Although there was a trend in stool weight reduction in children receiving ORS with PHGG (study vs. control, stool weight (g), mean +/- SD; 1st 24 hour, 854.03 +/- 532.15 vs. 949.11 +/- 544.33, p = 0.32; 2nd 24 hour, 579.84 +/- 466.01 vs. 761.26 +/- 631.64, p = 0.069; 3rd 24 hour, 385.87 +/- 454.09 vs. 495.73 +/- 487.61, p = 0.196), especially in 2nd 24 h period, the difference was not statistically significant. The mean time (day) to attain weight for length 80% of NCHS median without edema was significantly shorter in the study group (study vs. control, mean +/- SD, 4.5 +/- 2.6 vs. 5.7 +/- 2.8, p = 0.027). Conclusion: PHGG added to ORS substantially reduced duration of diarrhoea. It also enhanced weight gain. Further studies might substantiate to establish its beneficial effect.
引用
收藏
页数:9
相关论文
共 39 条
  • [21] Safety and Efficacy of Low-osmolarity ORS vs. Modified Rehydration Solution for Malnourished Children for Treatment of Children with Severe Acute Malnutrition and Diarrhea: A Randomized Controlled Trial
    Kumar, Ruchika
    Kumar, Praveen
    Aneja, S.
    Kumar, Virendra
    Rehan, Harmeet S.
    JOURNAL OF TROPICAL PEDIATRICS, 2015, 61 (06) : 435 - 441
  • [22] Antidiarrheal effects of L-histidine-supplemented rice-based oral rehydration solution in the treatment of male adults with severe cholera in Bangladesh: A double-blind, randomized trial
    Rabbani, GH
    Sack, DA
    Ahmed, S
    Peterson, JW
    Saha, SK
    Marni, F
    Thomas, P
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (09): : 1507 - 1514
  • [23] Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial
    Zeng, Ming
    Mao, Xu-Hu
    Li, Jing-Xin
    Tong, Wen-De
    Wang, Bin
    Zhang, Yi-Ju
    Guo, Gang
    Zhao, Zhi-Jing
    Li, Liang
    Wu, De-Lin
    Lu, Dong-Shui
    Tan, Zhong-Ming
    Liang, Hao-Yu
    Wu, Chao
    Li, Da-Han
    Luo, Ping
    Zeng, Hao
    Zhang, Wei-Jun
    Zhang, Jin-Yu
    Guo, Bo-Tao
    Zhu, Feng-Cai
    Zou, Quan-Ming
    LANCET, 2015, 386 (10002): : 1457 - 1464
  • [24] Does an L-glutamine-containing, glucose-free, oral rehydration solution reduce stool output and time to rehydrate in children with actue diarrhoea?: A double-blind randomized clinical trial
    Gutierrez, Claudia
    Villa, Sofia
    Mota, Felipe R.
    Calva, Juan J.
    JOURNAL OF HEALTH POPULATION AND NUTRITION, 2007, 25 (03) : 278 - 284
  • [25] Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents
    Sallee, Floyd
    Kohegyi, Eva
    Zhao, Joan
    McQuade, Robert
    Cox, Kevin
    Sanchez, Raymond
    van Beek, Alet
    Nyilas, Margaretta
    Carson, William
    Kurlan, Roger
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (09) : 771 - 781
  • [26] Multicenter randomized, double-blind controlled trial to evaluate the efficacy of laser therapy for the treatment of severe oral mucositis induced by chemotherapy in children: laMPO RCT
    Gobbo, Margherita
    Verzegnassi, Federico
    Ronfani, Luca
    Zanon, Davide
    Melchionda, Fraia
    Bagattoni, Simone
    Majorana, Alessandra
    Bardellini, Elena
    Mura, Rosamaria
    Piras, Alessandra
    Petris, Maria Grazia
    Mariuzzi, Maria Livia
    Barone, Angelica
    Merigo, Elisabetta
    Decembrino, Nunzia
    Vitale, Marina Consuelo
    Berger, Massimo
    Defabianis, Patrizia
    Biasotto, Matteo
    Ottaviani, Giulia
    Zanazzo, Giulio Andrea
    PEDIATRIC BLOOD & CANCER, 2018, 65 (08)
  • [27] Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial
    Sur, Dipika
    Lopez, Anna Lena
    Kanungo, Suman
    Paisley, Allison
    Manna, Byomkesh
    Ali, Mohammad
    Niyogi, Swapan K.
    Park, Jin Kyung
    Sarkar, Banawarilal
    Puri, Mahesh K.
    Kim, Deok Ryun
    Deen, Jacqueline L.
    Holmgren, Jan
    Carbis, Rodney
    Rao, Raman
    Van, Nguyen Thu
    Donner, Allan
    Ganguly, Nirmal K.
    Nair, G. Balakrish
    Battacharya, Sujit K.
    Clemens, John D.
    LANCET, 2009, 374 (9702): : 1694 - 1702
  • [28] Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial
    O'BHourihane, Jonathan
    Beyer, Kirsten
    Abbas, Allyah
    Fernandez-Rivas, Montserrat
    Turner, Paul J.
    Blumchen, Katharina
    Nilsson, Caroline
    Ibanez, Maria D.
    Deschildre, Antoine
    Muraro, Antonella
    Sharma, Vibha
    Erlewyn-Lajeunesse, Michel
    Manuel Zubeldia, Jose
    De Blay, Frederic
    Sauvage, Christine D.
    Byrne, Aideen
    Chapman, John
    Boralevi, Franck
    DunnGalvin, Audrey
    O'Neill, Charmaine
    Norval, David
    Vereda, Andrea
    Ben Skeel
    Adelman, Daniel C.
    du Toit, George
    LANCET CHILD & ADOLESCENT HEALTH, 2020, 4 (10): : 728 - 739
  • [29] Efficacy and safety of an oral tyrosine kinase 2 inhibitor VTX958 in moderately to severely active Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 trial
    Danese, S.
    Jairath, V
    Sands, B. E.
    Schreiber, S.
    Panaccione, R.
    D'Haens, G.
    Lindstrom, B.
    Liu, K.
    Sandborn, W.
    Rubin, D. T.
    Peyrin-Biroulet, L.
    Vermeire, S.
    Naik, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1852 - i1853
  • [30] Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to &lt;18 years - a randomized, double-blind, placebo-controlled trial
    Beuter, Christoph
    Volkers, Gisela
    Radic, Tatjana
    Goldberg, Jutta
    van den Anker, John
    JOURNAL OF PAIN RESEARCH, 2019, 12 : 3099 - 3112